Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Mucociliary ClearanceEnrolling Location: Florida, USA

    Study of BI 1265162, a mucus clearance drug, in teens and adults with CF. , protocol number NCT04059094 BI 1399-0003

    This study will look at the safety and effectiveness of BI 1265162, a drug intended to improve the clearance of mucus from the lungs. This study is for people with CF ages 12 and older.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      5

    • Length of Participation:

      7 weeks

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple care centres across the US

    Study to evaluate the effects of the triple-combination modulator, elexacaftor/texacaftor/ivacaftor (PROMISE) , protocol number NCT04038047 PROMISE

    This observational study will measure the effects of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor, in people with CF. These drugs are intended to help CFTR protein function closer to normal. This study will look at how treatment with the triple-combination therapy affects people with CF across many different aspects of the disease.

    • Age:

      12 Years and Older

    • Mutation(s):

      Two Copies F508del or One Copy F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      2 years

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Phase 2 study of PTI-808 triple-combination therapy in adults with cystic fibrosis who have at least one copy of the F508del mutation. , protocol number NCT03251092 PTI-808

    This study will look at the safety and tolerability of PTI-808, a modulator intended to help CFTR protein function closer to normal. PTI-808 will be tested in combination with two other modulators, PTI-801 and PTI-428.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del or One Copy F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      9

    • Length of Participation:

      10 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Study of ABBV-3067 and ABBV-2222 in adults with cystic fibrosis who have two copies of the F508del mutation. , protocol number NCT03969888 AbbVie ABBV-3067

    This study will look at the safety and effectiveness of ABBV-3067, a CFTR modulator intended to help CFTR protein function closer to normal. ABBV-3067 will be tested alone and in combination with another CFTR modulator, ABBV-2222. This study has two parts. In Part 1, participants will be randomly assigned to receive one of the following treatments: the study drug ABBV-3067 alone; both ABBV-3067 and ABBV-2222; or a placebo. In Part 2 of the study, some participants will receive both CFTR modulators ABBV-3067 and ABBV-2222, and some participants will receive a placebo. Researchers will test the effectiveness of ABBV-3067 alone and in combination with ABBV-2222 by measuring changes in lung function and sweat chloride. This study may require lung function tests and/or other measurements.

    • Age:

      18 years and Older

    • Mutation(s):

      Two Copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      5

    • Length of Participation:

      3 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Study to evaluate VX-121 in adults 18 years and older with cystic fibrosis , protocol number NCT03912233 VERTEX VX-18-121-101

    This study will look at the safety, tolerability, and effectiveness of the drug VX-121, a drug intended to help CFTR function closer to normal. This study will take place in two parts. Part 1 is randomized and placebo-controlled. This means that some participants will receive the study drug in combination with tezacaftor and VX-561, and some participants will receive placebo. Part 2 is a randomized, active-comparator trial. This means that some participants will receive the study drug in combination with tezacaftor and VX-561, and some participants will receive placebo in combination with tezacaftor and ivacaftor. In this study, researchers will test the safety and tolerability by monitoring for adverse events. They will test for effectiveness by measuring lung function. They will also monitor sweat chloride and how much of the drug stays in the body. This study may require sweat tests, lung function tests, blood samples and/or other measures.

    • Age:

      18 years and Older

    • Mutation(s):

      Two Copies F508del or One Copy F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      10

    • Length of Participation:

      17 weeks

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Multiple care centres across the US

    Study to evaluate inhaled molgramostim in adults 18 years and older with cystic fibrosis (Savara SAV008-02) , protocol number NCT03597347 SAVARA SAV008-02

    This study will look at the effectiveness of the inhaled drug molgramostim, a drug intended to treat infections in the lung. This study is open-label with no control. This means that all participants will receive the study drug. In this study, researchers will test the effectiveness of inhaled molgramostim by monitoring NTM cultures. They will also monitor lung function, BMI and quality of life. This study may require sputum samples, lung function tests and/or other measures.

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      30% or greater

    • Number of Visits:

      19

    • Length of Participation:

      72 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA & Australia

    Phase 3 study of inacaftor in babies who have a CFTR gating mutation , protocol number NCT02725567 VX15-770-124

    This two-part, open label study is taking place at multiple care centers across the US. It will look at the safety and effectiveness of ivacaftor, as well as how the body processes the drug, in babies who have a CFTR gating mutation.

    • Age:

      0 Months to 24 Months

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      8

    • Length of Participation:

      24 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple US sites & Australia

    Phase 2 study of VX-440 combination drug in people with cystic fibrosis. , protocol number NCT02951182 VX15-440-101

    This study is taking place at multiple care centres accross the US. It will look at the safety and effectiveness of the drug VX-440 in combination with ivacaftor and/or tezacaftor (VX-661)

    • Age:

      18 years and older

    • Mutation(s):

      homozygous or hetrozygous F508del

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      11

    • Length of Participation:

      57

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple care centres across the US

    GI symptoms observational study (GALAXY) , protocol number NCT03801993 GALAXY-OB-18

    This study will collect information on gastrointestinal (GI) symptoms that people with CF experience.

    • Age:

      2 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      1

    • Length of Participation:

      29 days

    Contact us about this clinical Trial >
  • OtherEnrolling Location: USA

    Study of SPI-1005 in people with CF ages 18 and older (Sound Pharma SPI-3005-501.2) , protocol number NCT02819856 SPI-3005-501.2

    This study will test the safety and tolerability of SPI-1005, a drug intended to prevent and treat hearing loss caused by aminoglycosides.

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40-100%

    • Number of Visits:

      6

    • Length of Participation:

      49 days

    Contact us about this clinical Trial >
  • Displaying results 91-100 (of 193)
     |<  <  6 - 7 - 8 - 9 - 10 - 11 - 12 - 13 - 14 - 15  >  >|